PharmaceuticalsSilver report

Published April 2026Insight Research12 min read2026 Edition12 sources, 12 primary-gradeStrong source depth

Thailand Diabetes, Insulin, Chronic Disease Pharma Deep Dive

Thai diabetes pharma ~THB 30-40B. ~5-6M Thai diabetic, ~1.5-2M on insulin. Novo Nordisk, Sanofi, Lilly, GLP-1, Thai generic GPO, Siam Pharm. NLEM, UC coverage.

Key takeaways

1
Thai diabetes, chronic-disease pharma ~ FY2024; diabetic population ~5- ( adults), ~1.5- on insulin.
2
Therapy mix: insulin ~, oral antidiabetic ~, GLP-1 ~, hypertension, cardiovascular ~, kidney, comorbid ~, other ~.
3
Insulin originators: Novo Nordisk, Sanofi, Eli Lilly. GLP-1: Novo (Ozempic/Wegovy semaglutide), Lilly (Mounjaro/Zepbound tirzepatide).
4
Coverage: UC Universal Coverage, Social Security, CSMBS Civil Servant cover NLEM essential medicines; private insurance, retail pharmacy, out-of-pocket cover newer GLP-1.
5
Local generic, biosimilar: GPO (state), Siam Pharmaceutical, LBS Laboratories, Thai Otsuka, Pharmagen produce metformin, SU, statin, insulin biosimilar.

Executive summary

Thai diabetes, chronic-disease pharma market reaches ~ FY2024. Diabetic population ~5- Thai (~ of adults; among ASEAN highest with Indonesia, Malaysia, Singapore comparable); ~1.5- on insulin therapy. Therapy class mix: Insulin (basal, bolus, pre-mix, biosimilar) ~; oral antidiabetic (metformin, sulfonylurea, DPP-4, SGLT-2, thiazolidinedione) ~; GLP-1 (semaglutide Ozempic/Wegovy, tirzepatide Mounjaro/Zepbound) ~ recent, premium, supply-constrained; cardiovascular hypertension, dyslipidaemia, statin ~; kidney, osteoporosis, neuropathy, retinopathy comorbid ~; other chronic ~.^{[, , , , ]}

Insulin originators dominate Thai market: Novo Nordisk Thailand (Danish parent) — leader with NovoMix, Levemir, Tresiba, Ryzodeg, Ozempic, Wegovy; Sanofi Thailand (French parent) — Lantus glargine, Toujeo, Lyxumia, Apidra; Eli Lilly Thailand (US parent) — Humalog, Trulicity, tirzepatide Mounjaro, Humulin. Insulin originator, biosimilar pricing: branded analogue ~ per pen vs Thai-produced biosimilar ~ per pen (post-2018 GPO, biosimilar entry). NLEM, UC procurement drives biosimilar uptake at public hospitals; private hospital, retail pharmacy mix originator, biosimilar. GLP-1 wave: semaglutide (Novo), tirzepatide (Lilly) — recent FDA, Thai FDA approval; supply-constrained globally in 2023-2024; premium-priced /month for diabetes, obesity; private out-of-pocket, private insurance coverage; UC, SSS, CSMBS coverage limited or excluded.^{[, , , ]}

Local generic, biosimilar, Thai FDA: Government Pharmaceutical Organization (GPO state) supplies UC, Social Security, CSMBS public-procurement insulin, metformin, sulfonylurea, statin, ACEI, ARB, diuretic, CCB; Siam Pharmaceutical, LBS Laboratories, Thai Otsuka, Pharmagen produce branded generic. Insulin biosimilar gradually entering with GPO, foreign biosimilar partnership. Thai Diabetes Association, Diabetic Association of Thailand publish clinical practice guidelines, therapy choice. MoPH NCD National Programme, screening (HbA1c, fasting glucose, OGTT), diabetes-care clinic, community health volunteer (อสม.) network drive case finding, treatment adherence. Universal Coverage Scheme National List of Essential Medicines (NLEM) reimburses essential generic, biosimilar; newer drug (GLP-1, DPP-4, SGLT-2 originator) often outside NLEM and limited to private, out-of-pocket, select private insurance.^{[, , , , , ]}

Thai FDA, MoPH, NHSO, GPO, Siam Pharm, LBS, Novo, Sanofi, Lilly, IDF, Thai DM Association, IQVIA, SCB EIC

Data as of: FY2024-Q1 2026

Thai diabetes, chronic-disease pharma therapy mix (% of FY2024 value)

Insulin (basal+bolus+pre-mix+biosimilar)

Share %

32%

Key brands, drivers

Novo Tresiba, Sanofi Lantus, Lilly Humalog, biosimilar

Oral antidiabetic

Share %

26%

Key brands, drivers

Metformin, sulfonylurea, DPP-4, SGLT-2, TZD

GLP-1 (semaglutide, tirzepatide)

Share %

12%

Key brands, drivers

Ozempic, Wegovy, Mounjaro, Trulicity premium

Hypertension, dyslipidaemia, cardiovascular

Share %

16%

Key brands, drivers

Statin, ACEI, ARB, CCB, diuretic, antiplatelet

Kidney, osteoporosis, neuropathy, retinopathy

Share %

Key brands, drivers

ESA, bisphosphonate, gabapentin, intra-vitreal anti-VEGF

Other chronic, comorbid

Share %

Key brands, drivers

Heart failure, thyroid, asthma, COPD

Therapy class	Share %	Key brands, drivers
Insulin (basal+bolus+pre-mix+biosimilar)	32%	Novo Tresiba, Sanofi Lantus, Lilly Humalog, biosimilar
Oral antidiabetic	26%	Metformin, sulfonylurea, DPP-4, SGLT-2, TZD
GLP-1 (semaglutide, tirzepatide)	12%	Ozempic, Wegovy, Mounjaro, Trulicity premium
Hypertension, dyslipidaemia, cardiovascular	16%	Statin, ACEI, ARB, CCB, diuretic, antiplatelet
Kidney, osteoporosis, neuropathy, retinopathy	8%	ESA, bisphosphonate, gabapentin, intra-vitreal anti-VEGF
Other chronic, comorbid	6%	Heart failure, thyroid, asthma, COPD

IQVIA, Thai FDA, GPO, Thai DM Association triangulation

Data as of: FY2024

Analyst framing

Why this report

Thai diabetes pharma is insulin-32%-anchored, GLP-1-12%-emerging, UC/SSS/CSMBS-NLEM-funded, Novo/Sanofi/Lilly-originator, GPO/Siam-Pharm-generic-biosimilar-led.

Insulin, GLP-1, generic, UC, retail, screening playbooks

Insulin originator: Novo Nordisk Thailand leader — NovoMix premix, Levemir basal, Tresiba ultralong, Ryzodeg combo, NovoRapid bolus, Fiasp ultra-rapid; large-pen, cartridge, vial portfolio, injection-pen ecosystem. Sanofi Thailand — Lantus glargine basal flagship, Toujeo concentrated basal, Lyxumia GLP-1, Apidra rapid-acting. Eli Lilly Thailand — Humalog rapid, Humulin standard, Trulicity weekly GLP-1, Mounjaro tirzepatide GLP-1/GIP dual, Humulog Mix. Insulin biosimilar: GPO, Indian, Korean biosimilar gradually entering Thai market post-2018; NLEM essential-medicine list, GPO public-procurement, UC, SSS scheme drives biosimilar uptake at public hospital; private, retail pharmacy mix originator, biosimilar at slower pace. Insulin pen-needle, glucometer, CGM (continuous glucose monitor) ecosystem accompanies — Roche, Abbott, Dexcom, Medtronic CGM premium emerging.

GLP-1 wave: Novo semaglutide (Ozempic for diabetes, Wegovy for obesity), Lilly tirzepatide (Mounjaro for diabetes, Zepbound for obesity) — recent FDA, Thai FDA approval; supply-constrained globally 2023-2024 driving Thai supply rationing, grey-market import; premium pricing THB 8,000-15,000/month direct-pay or insurance; insurance, private hospital, Bumrungrad, Samitivej, BDMS prescriber-led; UC, SSS, CSMBS coverage limited or excluded for diabetes-only indication; obesity GLP-1 entirely out-of-pocket. GLP-1 also being prescribed off-label for weight management among affluent, medical-tourist patient. Long-term implications: GLP-1, tirzepatide may displace some insulin in Type 2 diabetes; cost-effectiveness, UC inclusion under policy debate.

Generic, UC, retail, screening: Government Pharmaceutical Organization (GPO state) anchors UC, SSS, CSMBS public-procurement of metformin, sulfonylurea, statin, ACEI/ARB, diuretic, CCB, insulin biosimilar; Siam Pharmaceutical, LBS Laboratories, Thai Otsuka, Pharmagen, Olic, Berlin Pharmaceutical produce branded generic. Universal Coverage Scheme NLEM essential-medicine list defines reimbursable, procurement-eligible drugs; newer DPP-4, SGLT-2, GLP-1 originator, tirzepatide largely outside NLEM. Retail pharmacy: Boots, Watsons, Save Drug, Pharmacy Plus, Apex, Kingdom Pharma, chain, standalone — over-the-counter, prescription dispensing, chronic refill, diabetic, cardiovascular focus. MoPH NCD National Programme, Thai Diabetes Association clinical practice guidelines, community health volunteer screening, diabetes-care clinic, HbA1c, fasting glucose, OGTT, early-detection, treatment-adherence programmes drive case identification, maintenance.

Scenarios to 2031

Bull: GLP-1 scale, biosimilar, screening, tier coverage

Market THB ~55B

GLP-1 supply normalises, UC partially covers, private insurance covers; biosimilar insulin scales; screening, early-detection drive case finding; cardiovascular, kidney comorbid management.

Base case

Market THB ~42B

Steady population growth, premium GLP-1 private only; biosimilar gradual; screening modest improvement.

Bear: Thai FDA delays, supply, macro

Market THB ~32B

GLP-1 supply constrained; Thai FDA approval delays; macro softness compresses premium private; UC budget pressure.

Unlock the full report

Insulin, GLP-1, generic, UC, retail playbooks, scenarios.

Unlock deep dive·$149-$199

Need more than the web report? Ask for a scoped export or source appendix.

Every report keeps visible citations and source metadata. Terms.

Related reports

Thailand Life Sciences, Biotech, GPO BioPharm Deep Dive

Thai life-sci, biotech anchored by GPO (state generics, vaccine), Siam Bioscience (Crown Property biopharma — AstraZeneca COVID partner), Bumrungrad/BDMS clinical-trial sites, Mahidol/Chula research. EEC Genomics Thailand, biopharma investment incentive, ASEAN CRO hub positioning.

Open report →

Thailand Pharma Generic vs Branded Deep Dive

Deep-dive into Thai pharma generic vs branded dynamics. Thai pharma ~THB 250B. Generic ~60% vol / ~30% value; branded innovator ~40% vol / ~65% value; biosimilar, biotech ~5% value emerging. Thai generic: Siam Pharmaceutical (SET: SPC), Thai Nakorn Patana, Mega Lifesciences (SET: MEGA), Pharmahof, GPO state manufacturer. Biosimilar: Siam Bioscience (HM King-owned) produced AstraZeneca COVID-19 vaccine, insulin, HGH, monoclonal antibody biosimilars. Branded innovator: Pfizer, Novartis, Roche, GSK, Abbott, Sanofi, MSD Thailand. Patent cliff 2025-27 opens biosimilar entry on ~THB 5-10B originator biologics. FDA, DMS, Drug Act, Patent Act (2006-07 compulsory license precedents). NHSO UCS, CSMBS, SSO, NLEM drive generic substitution, procurement.

Open report →

Thailand Pharmaceuticals Market Intelligence

Thailand's pharmaceuticals market reached approximately THB 280B in FY2024, split roughly 75% imported (originators, generics) and 25% domestic (GPO state, listed, private generics). Government Pharmaceutical Organisation is the state anchor for essential medicines, ARV, biosimilar manufacturing. Mega Lifesciences (SET: MEGA) is the largest Thai-listed pharma (~THB 16B revenue). Multinational originator subsidiaries (GSK, Pfizer, Novartis, Roche) lead originator, specialty supply. UCS, SSS, CSMBS multi-payer framework, NLEM reimbursement drive price-competition dynamics.

Open report →

Thailand Diagnostic Lab & Imaging Deep Dive

Deep-dive into Thai diagnostic lab, medical imaging ~THB 55-70B FY2024. Hospital-integrated clinical labs at Bumrungrad, Samitivej, Bangkok Hospital, Piyavate, Ramkhamhaeng, public university hospitals; specialist reference labs (N Health, Thyrocare, LabPlus, Professional Laboratory); medical imaging (X-ray, CT, MRI, PET-CT, ultrasound, nuclear); point-of-care, home-test kits, digital diagnostic. Equipment imported from Siemens Healthineers, GE HealthCare, Philips, Roche, Abbott, Sysmex, Hitachi. 2020-2022 COVID testing surge boosted revenue; post-COVID corporate wellness, health screening, medical tourism return drive recovery. Regulation: Thai FDA MDCD, MoPH NCD screening.

Open report →